EMADINE
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMADINE is an ophthalmic solution approved in 1997 for eye-related conditions. It is a small-molecule drop formulation administered directly to the eye. The specific mechanism of action and indication are not disclosed in available data.
LOE Approaching
As LOE approaches, the brand team is likely consolidating; hiring focuses on defensive strategies and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EMADINE presents limited career growth opportunity; current roles focus on defending market share and managing decline. Professionals assigned to this product should expect eventual transition planning or portfolio reassignment as LOE approaches.
Brand ManagerMarket Access
Worked on EMADINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.